<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335670</url>
  </required_header>
  <id_info>
    <org_study_id>201708705</org_study_id>
    <secondary_id>P50CA174521</secondary_id>
    <nct_id>NCT03335670</nct_id>
  </id_info>
  <brief_title>Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors</brief_title>
  <official_title>Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yusuf Menda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor
      patients and if that distribution is consistent through repeated scans. This is an RDRC study
      - as such, the images obtained for this study cannot be used clinically or shared with
      treating oncologists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High grade neuroendocrine tumors often do not express somatostatin (sstr) receptors but often
      express the CXCR4 receptor. The CXCR4 receptor is a marker of poorly differentiated cells.
      Pentixafor is a peptide that targets these CXCR4 receptors. By combining it with gallium-68,
      a radionuclide, pentixafor can then be evaluated as an imaging agent to detect high-grade
      neuroendocrine tumors.

      [68Ga]Pentixafor is a radio-labelled imaging agent used for positron emission tomography
      (PET). The dose is small, known as a tracer dose. It is designed to capture information about
      the body and how the body is working without interfering or causing an effect.

      The goal of this study is to evaluate how the [68Ga]Pentixafor is distributed through the
      body after injection and how it is taken up by the organs of the body. The study will also
      examine if the imaging is reproducible to determine if the PET images show the same uptake of
      the study drug across different scans.

      This study is an RDRC study - the equivalent to a phase 0 study. The [68Ga]Pentixafor has not
      been shown to target tumors; specificity and sensitivity have not been established. For this
      reason, images obtained for this study cannot be used clinically or shared with treating
      oncologists.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine biodistribution (pharmacokinetic parameters) of [68Ga]Pentixafor in patients with neuroendocrine tumors (NETs)</measure>
    <time_frame>Within 1 month of [68Ga]Pentixafor scan</time_frame>
    <description>Biodistribution will be assessed through the radiotracer parameters standardized uptake value (SUV) and K-influx obtained from PET scan and blood samples.These values provide a pharmacokinetic profile of the investigational drug's biodistribution in the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the repeatability of [68Ga]Pentixafor uptake in known neuroendocrine tumor lesions</measure>
    <time_frame>Within 1 month of the second [68Ga]Pentixafor scan</time_frame>
    <description>Determine the difference, in any, of the biodistribution values between scans 1 and 2, for subjects who undergo 2 [68Ga]Pentixafor scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare standardized uptake values of [68Ga]Pentixafor and [68Ga]DOTATATE in known neuroendocrine tumor lesions</measure>
    <time_frame>Within 6 months of [68Ga]Pentixafor scan</time_frame>
    <description>The standardized uptake value (SUV) of known neuroendocrine tumors for the investigational agent [68Ga]Pentixafor will be compared to the SUV for [68Ga]DOTATATE (NetSpot).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate the uptake of [68Ga]Pentixafor and [68Ga]DOTATATE (NetSpot) in known neuroendocrine tumor lesions with expression of receptors (CXCR4 and SSTR2) in biopsy tissue samples.</measure>
    <time_frame>Within 6 months of [68Ga]Pentixafor scan</time_frame>
    <description>The standardized uptake value (SUV) of the gallium PET tracers ( [68Ga]Pentixafor and/or [68Ga]DOTATATE) will be compared to the receptor expression score (H-score)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>[68Ga]Pentixafor PET scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]Pentixafor</intervention_name>
    <description>68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor</description>
    <arm_group_label>[68Ga]Pentixafor PET scan</arm_group_label>
    <other_name>(68Ga)pentixafor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Histological diagnosis of neuroendocrine tumor (NET).

          3. Had a prior 68Ga DOTATATE PET/CT scan (NetSpot) and a CT or MRI with or without
             contrast performed within 3 months before signing the consent, without interval
             treatment other than a somatostatin analog.

          4. CT or MRI must demonstrate at least one lesion (primary or metastatic) present 1.5 cm
             or larger in any dimension on cross-sectional imaging (CT or MRI) obtained within 3
             months of study enrollment.

          5. Results of CXCR4 immunohistochemistry or slides from biopsy of primary tumor or
             metastatic lesions available for study analysis.

          6. Participation in the Iowa Neuroendocrine Tumor Registry.

        Exclusion Criteria:

          1. Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection requiring hospitalization, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
             would limit compliance with study requirements.

          2. Physical limitation that would limit compliance with the study requirements

          3. Pregnant or lactating women. Should a woman become pregnant or suspect she is pregnant
             while participating in this study, she should inform her treating physician
             immediately. A negative pregnancy test will be required for all female subjects with
             child bearing potential.

          4. Planned administration of any NET therapy between scan 1 and 2, except for
             Somatostatin analog.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Menda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Sue O'Dorisio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica Howsare, AA, MA</last_name>
    <phone>(319) 384-6469</phone>
    <email>veronica-howsare@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Gaimari-Varner, RN, BSN</last_name>
    <phone>(319) 384-5489</phone>
    <email>kristin-gaimari-varner@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Howsare, AA, MA</last_name>
      <email>veronica-howsare@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Gaimari-Varner, RN, BSN</last_name>
      <phone>(319) 384-5489</phone>
      <email>kristin-gaimari-varner@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yusuf Menda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. S. O'Dorisio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gideon Zamba, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Bellizzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Berg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Bushnell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chandrikha Chandrasekharan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Dick, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Dillon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Dunnwald, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Gaimari-Varner, RN, BSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Ghobrial, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael M. Graham, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Howsare, AA, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon Lehman, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas O'Dorisio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Pollard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Ponto, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Schall, RN, BSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Sunderland, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lapa C, Lückerath K, Kleinlein I, Monoranu CM, Linsenmann T, Kessler AF, Rudelius M, Kropf S, Buck AK, Ernestus RI, Wester HJ, Löhr M, Herrmann K. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. Theranostics. 2016 Jan 25;6(3):428-34. doi: 10.7150/thno.13986. eCollection 2016.</citation>
    <PMID>26909116</PMID>
  </reference>
  <reference>
    <citation>Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, Wester HJ, Kropf S, Lapa C, Schirbel A, Buck AK, Herrmann K. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. Clin Nucl Med. 2017 Jan;42(1):e29-e34.</citation>
    <PMID>27819856</PMID>
  </reference>
  <reference>
    <citation>Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. Epub 2016 May 12.</citation>
    <PMID>27175029</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Yusuf Menda</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>68Ga-pentixafor</keyword>
  <keyword>(68Ga)pentixafor</keyword>
  <keyword>Gallium Radioisotopes</keyword>
  <keyword>CXCR4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be shared upon request to the study's principal investigator. A signed usage agreement will need to be provided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

